As insurers confined coverage of behavioral soreness therapy, biopharmaceutical suppliers sensed a chance. Pharmaceutical innovation propagated prolonged-launch formulations, transdermal patches, nasal sprays, and oral dissolving strips. Clinical system companies drove a proliferation of novel soreness-modulating implants. By 2000, chronic agony wa